Humanscape RareNote: H1 Sales Surpass Last Year's Annual Total

'Rarenote,' Leading Innovation in Drug Cost Support for Rare Diseases, Dominates the Market with Overwhelming Growth! 'Rarenote,' a platform exclusively for rare disease and cancer patients developed by digital healthcare company Humanscape, is garnering market attention by recording overwhelming growth. Following a 3.3-fold surge in 2024 revenue compared to the previous year, in the first half of 2025, it has already surpassed the entire annual revenue of 2024, achieving a remarkable feat and proving the platform's explosive growth potential and strong market demand. Rarenote is an innovative approach aimed at alleviating the financial burden on patients for high-cost drug treatments and resolving information asymmetry issues. Through close cooperation with pharmaceutical companies, it operates a drug cost support program and has digitized the entire process of application, review, and result notification, which was previously done manually. This way, it dramatically improves information accessibility and convenience for patients while providing a win-win solution that offers overwhelming operational efficiency to pharmaceutical companies. In approximately 6 months since its service launch, it has provided practical treatment cost support benefits to over 100 patients, creating a positive social impact in a short period. Currently, it is actively collaborating and expanding its partnerships with leading domestic and international pharmaceutical companies such as AstraZeneca and BeiGene Korea. Rarenote plans to expand its support program to a total of 5 diseases by the second half of this year and disburse patient support funds totaling approximately 2.5 billion Korean Won. By making its digital-based drug cost support program a core service, contributing to improving the quality of life for rare disease and cancer patients, it is strongly anticipated to continue its sustainable growth. Humanscape emphasizes that Rarenote, based on data-driven accessibility and excellent operational efficiency, has firmly established itself as a reliable key partner for pharmaceutical companies while providing practical help to patients. It also revealed its vision to continue delivering innovative value to more patients and partners through sustainable business growth and lead the improvement of the rare disease treatment environment in the future.